RPTX - Roche signs licensing deal with Repare Therapeutics for tumor candidate

Repare Therapeutics (NASDAQ:RPTX) climbed ~17% in the post-market Wednesday after the clinical-stage precision oncology company announced a worldwide license and collaboration agreement with Swiss pharma giant Roche (OTCQX:RHHBY) (OTCQX:RHHBF) for its leading cancer candidate RP-3500. The oral experimental drug also known as camonsertib is designed to target tumors with specific genetic mutations including those in the ATM gene. Per the terms, Roche (OTCQX:RHHBY) will take over the development of RP-3500 with potential to expand its studies into additional tumors and combination therapeutic regimens. In return, Repare (RPTX) will receive $125M in upfront payments and up to $1.2 billion in additional payments subject to achievement of development, regulatory, commercial and sales milestones. The company is also eligible to receive royalties on global net sales of camonsertib ranging from high-single-digits to high-teens.

For further details see:

Roche signs licensing deal with Repare Therapeutics for tumor candidate